TABLE 1.—ESTIMATES OF ANNUALIZED HOUR BURDEN TO RESPONDENTS—Continued

Type of respondent	Number of respondents	Frequency of response	Average hours per response	Total hours (3 yr)	Annual hour burden
Post-focus group evaluation					
Kazakhstan villagers (adults ≥70 yrs old)	128	1	0.1	13	4.3
Total	128	1	2.0	256	85.3

There are no capital, operating or maintenance costs to report.

Request For Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proposed performance of the functions of the agency, including whether the information shall have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Kiyohiko Mabuchi, Principal Investigator, National Cancer Institute, Executive Plaza South, Room 7038, MSC 7238, Bethesda, Maryland 20852, or call non-toll free number 301–594–7469 or FAX your request, including your address to 301–402–0207.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received within 30 days of this publication.

Dated: May 21, 2007.

Rachelle Ragland-Greene,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. E7–10331 Filed 5–29–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

A Fullerene-Based Anticoagulant

Description of Technology: This technology relates to the use of substituted or modified C_{60} fullerenes, which are carbon-based molecular cages that resemble soccer balls, for the prevention or treatment of thrombosis, peripheral arterial occlusion, and catheter obstruction. Described are compositions and methods for administering such compounds at the implantation site of an in-dwelling device and methods of coating in-dwelling devices with such compounds. Such devices include stents, stent grafts, pacemakers, defibrillators, venous valves, heart valves, sutures, catheters, and drug delivery ports.

Applications: Non-invasive method of preventing clot formation.

Market: Anticoagulation therapy averages several billion dollars a year.

Further Research Required: Anti-coagulant properties of C–60 derivatives in vivo; Device coating and in vivo efficacy; Safety evaluation of device, in vivo models.

Inventors: Marina Dobrovolskaia *et al.* (NCI)

Patent Status: PCT Application No. PCT/US2006/041838 filed 25 Oct 2006 (HHS Reference No. E–140–2006/0 PCT–01)

Licensing Status: Available for licensing.

Licensing Contact: Fatima Sayyid, M.H.P.M.; 301/435–4521; *sayyidf@mail.nih.gov*

Aminoalkyl Substituted O^6-Benzylguanine Derivatives as Inactivators of O^6-Alkylguanine-DNA Alkyltransferase and Adjuvants for Chemotherapy

Description of Technology: This present invention describes novel class of compounds that inactivate the DNA repair protein O^6-alkylguanine-DNA alkyltransferase (AGT). Inactivation of this protein improves therapeutic effectiveness of chemotherapy drugs that modify O^6-position of DNA guanine residues.

These new compounds have several advantages over the existing O^6-benzylguanine compounds in terms of being more water soluble, being more potent, and the compounds are more readily formulated in water or phosphate buffered saline solutions than O^6-benzylguanine compounds.

The existing O^6-benzylguanine compounds are currently in Phase II and III clinical trials. The new aminoalkyl substituted O^6-benzylguanine derivatives are currently in preclinical trials.

Applications and Modality: New compounds have potential to improve chemotherapy treatment with anticancer agents; New compounds are more water soluble, more readily formulated and more potent than existing O^6-benzylguanine compounds.

Market: 600,000 deaths from cancer related diseases were estimated in 2006; In 2006, cancer drug sales were estimated to be $25 billion.

Development Status: The technology is currently in the pre-clinical stage of development.

Inventors: Robert C. Moschel (NCI) *et al.*

Relevant Publication: A manuscript directly related to the above technology will be available as soon as it is accepted for publication.

Patent Status: U.S. Patent Application No. 11/683,310 filed 07 Mar 2007 (HHS Reference No. E–307–2004/1–US–01).

Licensing Status: Available for exclusive and non-exclusive licensing.

Licensing Contact: Adaku Nwachukwu, J.D.; 301/435–5560; *madua@mail.nih.gov*.

Inhibition of ABC Transporters by Transmembrane Domain Analogs

Description of Technology: ABC transporters contain multiple transmembrane domains and are involved in the translocation of a variety of substrates across cell membranes. Upregulation of these transporters contributes to multiple drug resistance in cancer chemotherapy wherein these transporters export chemotherapeutic agents out of cancer cells. The inventors have found that P-glycoprotein and ABCG2 transporter can be effectively inhibited by properly modified peptides corresponding to certain transmembrane domains. This inhibition can be used to overcome drug resistance in resistant tumors.

Applications: Therapeutics that enhance cancer treatments.

Market: Cancer is the second leading cause of death in the United States; 600,000 deaths caused by cancer in 2006; Worldwide incidence of new cancer patients is forecast to increase from 4.2 million cases in the major cancer markets in 2005 to 4.6 million in 2010; Global anticancer market was worth over $42 billion in 2005 and by 2010, the global cancer market is expected to generate sales in excess of $60 billion.

Development Status: The technology is currently in the pre-clinical stage of development.

Inventors: Nadya I. Tarasova *et al.* (NCI)

Publications:

1. NI Tarasova *et al.* Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem. 2005 Jun 2;48(11):3768–3775.

2. NI Tarasova *et al.* Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J Biol Chem. 1999 Dec 3;274(49):34911–34915.

Patent Status: U.S. Patent Application No. 10/130,192 filed 13 May 2002 (HHS Reference No. E–019–2000/2–US–02); PCT Patent Application No. PCT/US2000/31817 filed 17 Nov 2000 (HHS Reference No. E–019–2000/2–PCT–01); U.S. Provisional Patent Application No. 60/166,767 filed 22 Nov 1999 (HHS Reference No. E–019–2000/1–US–01); U.S. Provisional Patent Application No. 60/166,382 filed 18 Nov 1999 (HHS Reference No. E–019–2000/0–US–01).

Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: Jennifer Wong; 301/435–4633; *wongje@mail.nih.gov*.

Collaborative Research Opportunity: The National Cancer Institute's Structural Biophysics Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize inhibitors of multiple drug resistance proteins. Please contact John D. Hewes, Ph.D. at 301–435–3121 or *hewesj@mail.nih.gov* for more information.

Dated: May 21, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7–10332 Filed 5–29–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group; Subcommittee F—Manpower & Training; NCI–F.

Date: June 13–14, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

Contact Person: Lynn M. Amende, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8105, Bethesda, MD 20892, 301–451–4759, *amendel@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel; CA 07–505, ''The American College of Radiology Imaging Network (ACRIN) (Limited Competition U01).''

Date: June 20–21, 2007.

Time: 5 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Park Hyatt Philadelphia, Broad and Walnut Streets, Philadelphia, PA 19102.

Contact Person: Kenneth L. Bielat, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 7147, Bethesda, MD 20852, 301–496–7576, *bielatk@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 22, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–2664 Filed 5–29–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center on Minority Health and Health Disparities; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose